Clinical Trials Browser

Terminated × INDUSTRY × aldesleukin × Clear all

NCT05194735 2025-11-10

Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

NCT05207722 2024-12-12

CYNK-101 in Combination with Trastuzumab and Pembrolizumab in Patients with Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma

Phase 1/2 Terminated

1 enrolled

Gastrointestinal

Stomach Neoplasms

NCT01856023 2023-12-05

PROCLIVITY02

Phase 4 Terminated

29 enrolled 9 charts

Dermatologic

Melanoma, Neoplasm Metastasis, Skin Neoplasms

NCT04551885 2023-09-21

FT516 in Combination With Monoclonal Antibodies in Advanced Solid Tumors

Phase 1 Terminated

12 enrolled

BreastDermatologicGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Merkel Cell, Triple Negative Breast Neoplasms

NCT01683188 2021-02-01

PROCLIVITY01

Phase 4 Terminated

53 enrolled

Dermatologic

Melanoma, Skin Neoplasms

NCT00485563 2012-03-08

A Phase II Study of EC17 (Folate-hapten Conjugate) in Patients With Progressive Metastatic Renal Cell Carcinoma

Phase 2 Terminated

12 enrolled

Genitourinary

Carcinoma, Renal Cell, Neoplasm Metastasis, Neoplasms

NCT00250861 2008-04-21

Trial of Outpatient Immunotherapy With Rituximab and Aldesleukin (IL-2) vs. Rituximab Alone for Non-Hodgkin's Lymphoma

Phase 2 Terminated

110 enrolled

Lymphoid

Lymphoma, Non-Hodgkin